What are the indications, recommended dosing regimens, contraindications, required baseline assessments and monitoring, and common adverse effects of goserelin?

Goserelin: Clinical Overview

Indications

Goserelin is FDA-approved for five primary indications: prostate cancer (both advanced and locally advanced stage B2-C), endometriosis, endometrial thinning before ablative procedures, advanced breast cancer in premenopausal women, and ovarian function suppression (OFS) in hormone receptor-positive breast cancer 1.

Oncologic Indications:

• Prostate Cancer: Advanced disease and locally advanced (Stage B2-C) in combination with radiation therapy 2, 1
• Breast Cancer:
  • Advanced disease in premenopausal/perimenopausal women 1
  • Adjuvant OFS for hormone receptor-positive (HR+) breast cancer in premenopausal patients at higher risk (young age, high-grade tumor, lymph node involvement) 3

Gynecologic Indications:

• Endometriosis: Symptom management and lesion resolution 1
• Endometrial thinning: Pre-surgical preparation for ablative procedures 1
• Uterine fibroids: Pre-surgical treatment to reduce size and operative blood loss 4

---

Dosing Regimens

Standard Dosing:

Two formulations are available with equivalent efficacy:

• 3.6 mg subcutaneous depot every 4 weeks (monthly) 3, 1
• 10.8 mg subcutaneous depot every 12 weeks (quarterly) 3, 1

The 10.8 mg quarterly formulation demonstrates superior adherence (64.4-75.0% vs 45.4%) and longer treatment duration compared to monthly dosing, with non-inferiority confirmed in real-world studies 5, 6. Patients who switch to quarterly dosing show 65% still on treatment at 2 years versus 30-40% with monthly dosing 5.

Indication-Specific Dosing:

Breast Cancer (OFS):

• Duration: 5 years optimal based on SOFT/TEXT trials 3
• Minimum: 2 years encouraged (8-year DFS: 85.4% with OFS+tamoxifen vs 80.2% tamoxifen alone) 3
• Initiation: Start with chemotherapy (if given) OR alone for 1-2 cycles until estradiol reaches postmenopausal range before adding aromatase inhibitor 3

Prostate Cancer:

• Continue indefinitely for palliation 2, 1
• For locally advanced disease: Use with radiation therapy 2

Endometriosis:

• 6 months duration 1

Endometrial Thinning:

• 1-2 depot injections before surgery 1

---

Contraindications

Absolute Contraindications:

• Pregnancy (Category X/D depending on indication) 1
• Hypersensitivity to goserelin, GnRH agonists, or any component 1

Relative Contraindications/Cautions:

• Undiagnosed vaginal bleeding 1
• Women of childbearing potential not using non-hormonal contraception 1

---

Baseline Assessments

Before Initiating Therapy:

For All Patients:

• Pregnancy test (women of childbearing potential) 1
• Baseline cardiovascular assessment (history of QT prolongation, arrhythmias) 1
• Baseline glucose/HbA1c (diabetes risk) 1
• Baseline bone mineral density (especially if risk factors present) 1

For Breast Cancer Patients:

• Menopausal status assessment (critical for treatment planning) 3
• Baseline estradiol and FSH/LH levels if under age 60 and amenorrheic ≤12 months 3

For Prostate Cancer Patients:

• Baseline PSA 2
• Baseline testosterone 2
• Serum calcium (hypercalcemia risk with bone metastases) 1

---

Monitoring Requirements

Hormonal Monitoring (Breast Cancer):

Monitor estradiol and FSH/LH levels in the following scenarios 3:

• Under age 60 and amenorrheic ≤12 months before starting therapy
• After chemotherapy-induced amenorrhea
• After switching from tamoxifen to aromatase inhibitor
• Prior to next GnRH agonist dose, particularly in women under age 45 (frequency individualized)
• If vaginal bleeding occurs while on aromatase inhibitor (contact physician immediately) 3

Critical caveat: Menopausal status cannot be determined while receiving OFS 3. Aromatase inhibitors can paradoxically stimulate ovarian function 3.

General Monitoring:

• Tumor flare monitoring: First 1-2 weeks in prostate cancer (worsening bone pain, urinary obstruction, spinal cord compression) 1
• Glucose monitoring: Periodic assessment for hyperglycemia/diabetes 1
• Cardiovascular monitoring: ECG if QT risk factors present 1
• Bone mineral density: Periodically during long-term therapy 1
• Injection site assessment: Each administration 1

Disease-Specific Monitoring:

• Prostate cancer: PSA, testosterone levels 2
• Breast cancer: Clinical breast exam, imaging per standard guidelines 3

---

Common Adverse Effects

Most Common (>10% incidence):

Hypoestrogenic Effects (Both Sexes):

• Hot flashes/flushes: 75.9% in women, very common in men 7, 8
• Decreased libido: 47.4% 7, 8
• Sexual dysfunction: Erectile dysfunction in men 9
• Vaginal dryness (women)
• Mood changes/depression 1

Metabolic Effects:

• Weight gain
• Peripheral edema
• Hyperglycemia/diabetes exacerbation 1

Musculoskeletal:

• Bone mineral density loss (reversible after discontinuation) 1
• Arthralgia

Injection Site:

• Local reactions (minimal with proper technique) 9

Serious but Less Common:

Tumor Flare (First 1-2 Weeks):

• Prostate cancer: Worsening bone pain, urinary obstruction, spinal cord compression 1
• Breast cancer: Transient disease worsening 1
• Mitigation: Consider concurrent antiandrogen in prostate cancer 2

Cardiovascular:

• QT prolongation 1
• Increased cardiovascular events (particularly in men with pre-existing disease) 1
• Arrhythmias 1

Metabolic:

• Hypercalcemia (prostate cancer with bone metastases) 1

Newly Identified Signals (Real-World Data):

• Neutropenia, jaundice, pleural effusion (not currently in label) 10
• Interstitial lung disease (stronger association in males) 10

Sex and Age Disparities:

Males show higher mortality rates, more serious adverse events, and greater susceptibility to general disorders 10. Peak ADEs occur in males aged 65-74 years and females aged 40-54 years 10.

---

Administration Technique

Subcutaneous injection into the anterior abdominal wall 1:

• Use aseptic technique
• Some patients may require local anesthetic 9
• Biodegradable depot releases drug continuously over dosing interval 7, 11
• Do not attempt to remove depot once implanted 1

---

Special Populations

Renal/Hepatic Impairment:

No dose adjustment required 1

Pregnancy/Lactation:

Absolutely contraindicated in pregnancy 1. Discontinue if pregnancy occurs. Unknown if excreted in breast milk 1.

Pediatric:

Safety and efficacy not established 1

---

Clinical Pearls

For breast cancer OFS: The quarterly 10.8 mg formulation offers practical advantages with superior adherence and should be strongly considered over monthly dosing 5, 6.

Combination therapy: In prostate cancer, combined androgen blockade (goserelin + antiandrogen like bicalutamide) shows OS benefit (HR 0.78, P=0.0498) 2. In breast cancer, goserelin + tamoxifen or aromatase inhibitor is standard for high-risk premenopausal patients 3.

Add-back hormone therapy: Consider low-dose estrogen/progestin add-back to mitigate hypoestrogenic symptoms in benign gynecologic conditions 11.